JP2019508491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508491A5 JP2019508491A5 JP2018560449A JP2018560449A JP2019508491A5 JP 2019508491 A5 JP2019508491 A5 JP 2019508491A5 JP 2018560449 A JP2018560449 A JP 2018560449A JP 2018560449 A JP2018560449 A JP 2018560449A JP 2019508491 A5 JP2019508491 A5 JP 2019508491A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- pharmaceutical composition
- composition according
- inhibitor
- dna damaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 101700004551 BRAF Proteins 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 102200055464 BRAF V600E Human genes 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 102100009279 KRAS Human genes 0.000 claims 2
- 101710033922 KRAS Proteins 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102220197820 rs121913227 Human genes 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- NOFOAYPPHIUXJR-APNQCZIXSA-N Aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 229960001561 Bleomycin Drugs 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 208000000409 Breast Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 229960000684 Cytarabine Drugs 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 230000000970 DNA cross-linking Effects 0.000 claims 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N Dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 229940121647 EGFR inhibitors Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 Mitoxantrone Drugs 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 1
- 210000002307 Prostate Anatomy 0.000 claims 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N Pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims 1
- INSACQSBHKIWNS-QZQSLCQPSA-N Rebeccamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 229960002465 dabrafenib Drugs 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- -1 phototemstin Chemical compound 0.000 claims 1
- 229960001237 podophyllotoxin Drugs 0.000 claims 1
- 229930001140 podophyllotoxin Natural products 0.000 claims 1
- 229960000611 pyrimethamine Drugs 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
Claims (15)
- 対象における腫瘍の治療のための、DNA損傷剤及びB−raf阻害剤を含む医薬組成物であって、前記腫瘍は、野生型B−rafとして特性決定される、上記医薬組成物。
- 前記B−raf阻害剤は、ベムラフェニブ、ダブラフェニブ、またはソラフェニブ、あるいはそれらの薬学上許容される塩である、請求項1に記載の医薬組成物。
- 前記DNA損傷剤は、ゲムシタビン、5−FU、シタラビン、メトトレキセート、ピリメタミン、ブレオマイシン、オキサリプラチン、シスプラチン、エトポシド、ドキソルビシン、ビノレルビン、ミトキサントロン、ポドフィロトキシン、アフィディコリン、ホテムスチン、カルムスチン、S−23906、S39、SN−38、トポテカン、カンプトテシン、レベッカマイシン、またはそれらの任意の薬学上許容される塩である、請求項1に記載の医薬組成物。
- 前記B−raf阻害剤またはその薬学上許容される塩、及び前記DNA損傷剤は、順次、同時、または重複する様式での投与のために配合される、請求項1に記載の医薬組成物。
- 前記DNA損傷剤は、前記B−raf阻害剤の前の投与のために配合される、請求項1に記載の医薬組成物。
- 前記対象は、前記B−raf阻害剤の投与の前に、前記DNA損傷剤で前処置を受ける、請求項1に記載の医薬組成物。
- 前記腫瘍は、膵臓腫瘍、黒色腫腫瘍、肺腫瘍、結腸腫瘍、卵巣腫瘍、前立腺腫瘍、または乳腫瘍である、請求項1に記載の医薬組成物。
- 前記腫瘍は、野生型KRASを含む、請求項1に記載の医薬組成物。
- 前記腫瘍は、変異型KRASを含む、請求項1に記載の医薬組成物。
- さらに、MEK阻害剤またはEGFR阻害剤を含む、請求項1に記載の医薬組成物。
- 前記腫瘍は、BRAF V600EまたはV600K変異を持たない、請求項1に記載の医薬組成物。
- 前記治療は、さらに、治療前に前記対象に由来する腫瘍試料中のBRAF V600EまたはV600K変異の有無を検出することを含む、請求項1に記載の医薬組成物。
- 前記腫瘍は、転移性腫瘍または薬物耐性腫瘍である、請求項1に記載の医薬組成物。
- 前記DNA損傷剤は、DNA二本鎖切断またはDNA一本鎖切断を引き起こす作用剤である、請求項1に記載の医薬組成物。
- 前記DNA損傷剤は、DNA架橋剤、トポイソメラーゼ阻害剤、ポリメラーゼ阻害剤、またはアルキル化剤である、請求項1に記載の医薬組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291931P | 2016-02-05 | 2016-02-05 | |
US62/291,931 | 2016-02-05 | ||
US201662344612P | 2016-06-02 | 2016-06-02 | |
US62/344,612 | 2016-06-02 | ||
US201662424792P | 2016-11-21 | 2016-11-21 | |
US62/424,792 | 2016-11-21 | ||
PCT/US2017/016531 WO2017136741A1 (en) | 2016-02-05 | 2017-02-03 | Combinations to treat cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019508491A JP2019508491A (ja) | 2019-03-28 |
JP2019508491A5 true JP2019508491A5 (ja) | 2020-03-12 |
Family
ID=59500971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018560449A Pending JP2019508491A (ja) | 2016-02-05 | 2017-02-03 | がん治療用組み合わせ |
Country Status (9)
Country | Link |
---|---|
US (1) | US10898473B2 (ja) |
EP (1) | EP3411073A4 (ja) |
JP (1) | JP2019508491A (ja) |
KR (1) | KR20180118141A (ja) |
CN (1) | CN109069646A (ja) |
AU (1) | AU2017214574A1 (ja) |
CA (1) | CA3013342A1 (ja) |
HK (1) | HK1259445A1 (ja) |
WO (1) | WO2017136741A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3013342A1 (en) | 2016-02-05 | 2017-08-10 | Evol Science LLC | Combinations to treat cancer |
CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
CN111065414A (zh) | 2017-08-07 | 2020-04-24 | 埃沃尔科学有限责任公司 | 用以治疗癌症的组合 |
JP7126556B2 (ja) | 2018-09-28 | 2022-08-26 | 富士フイルム株式会社 | シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤 |
WO2020112627A1 (en) * | 2018-11-28 | 2020-06-04 | Evol Science LLC | Combinations of parp inhibitors and mapk activators to treat cancer |
US20230060581A1 (en) * | 2020-02-10 | 2023-03-02 | Cedars-Sinai Medical Center | Method of treating pancreatic cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100160381A1 (en) * | 2007-05-23 | 2010-06-24 | Novartis Ag | RAF Inhibitors for the Treatment of Thyroid Cancer |
US9707186B2 (en) * | 2012-02-21 | 2017-07-18 | Amrita Vishwa Vidyapeetham | Core-shell particle formulation for delivering multiple therapeutic agents |
US10220051B2 (en) | 2012-03-29 | 2019-03-05 | Institute For Cancer Research | Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer |
GB201320729D0 (en) * | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
JP6678585B2 (ja) * | 2013-12-20 | 2020-04-22 | バイオメッド バレー ディスカバリーズ,インコーポレイティド | Erk阻害剤およびraf阻害剤の組み合わせを使用するがん処置 |
CA3013342A1 (en) | 2016-02-05 | 2017-08-10 | Evol Science LLC | Combinations to treat cancer |
EP3768236A1 (en) | 2018-03-20 | 2021-01-27 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for cancer treatment |
-
2017
- 2017-02-03 CA CA3013342A patent/CA3013342A1/en not_active Abandoned
- 2017-02-03 CN CN201780018656.8A patent/CN109069646A/zh active Pending
- 2017-02-03 KR KR1020187025427A patent/KR20180118141A/ko unknown
- 2017-02-03 EP EP17748285.8A patent/EP3411073A4/en not_active Withdrawn
- 2017-02-03 AU AU2017214574A patent/AU2017214574A1/en not_active Abandoned
- 2017-02-03 US US16/074,881 patent/US10898473B2/en active Active
- 2017-02-03 WO PCT/US2017/016531 patent/WO2017136741A1/en active Application Filing
- 2017-02-03 JP JP2018560449A patent/JP2019508491A/ja active Pending
-
2019
- 2019-02-01 HK HK19101849.0A patent/HK1259445A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019508491A5 (ja) | ||
Reilly et al. | Exploiting DNA repair defects in colorectal cancer | |
Sachdev et al. | PARP inhibition in cancer: an update on clinical development | |
Selim et al. | Targeted and novel therapy in advanced gastric cancer | |
JOP20190154B1 (ar) | بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم | |
JP2018516911A5 (ja) | ||
JP2016525097A5 (ja) | ||
JP2018531226A5 (ja) | ||
RU2015143437A (ru) | Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака | |
JP2012523435A5 (ja) | ||
Shitara et al. | Advances in systemic therapy for metastatic or advanced gastric cancer | |
WO2007013480A3 (en) | Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex | |
JP2017533963A5 (ja) | ||
RU2017119066A (ru) | Композии апилимода и способы их применения в лечении колоректального рака | |
JP2011520921A5 (ja) | ||
Gautschi et al. | Bevacizumab, pemetrexed, and cisplatin, or bevacizumab and erlotinib for patients with advanced non–small-cell lung cancer stratified by epidermal growth factor receptor mutation: Phase II Trial SAKK19/09 | |
JP2017517520A5 (ja) | ||
Gafton et al. | Hepatocellular carcinoma: insights in the biological treatment beyond sorafenib | |
Oneda et al. | Adjuvant treatment of colon cancer with microsatellite instability–the state of the art | |
WO2014165412A3 (en) | Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate | |
Dy et al. | Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non–small-cell lung cancer | |
Wang et al. | PARP inhibitors in small cell lung cancer: the underlying mechanisms and clinical implications | |
JP2018509478A5 (ja) | ||
Zorn | PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check | |
WO2014168801A3 (en) | Methods and compositions for treating cancer |